ClinicalTrials.gg
RecruitingNCT06180382VEDIANUpdated May 5, 2026

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

A Phase 4 interventional study of Adalimumab and Vedolizumab in Crohn's Disease, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 12 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Planned enrollment
12th of 42
220 · median 143
Started
2024
the only one that year
Phase 4
13 of 42
4 open now
Registered
41st of 42
by date
Lead sponsor
1 of 42
Centre Hospitalier Universitaire de Saint Etienne

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 12th largest by planned enrollment, is the only one that started in 2024, is one of 13 in phase 4, and was the 41st registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

A substantial fraction of IBD patients with an initial response to infliximab or adalimumab later experience re-emerging active disease despite ongoing anti-Tumour Necrosis Factor (TNF) agents maintenance therapy. The optimal intervention in patients with secondary loss-of-response (LOR) is still poorly defined, as there are still scant data on how best to choose the next intervention from among dose-intensification, switch to another anti-TNF or switch out of the anti-TNF class. Moreover, according to STRIDE 2 recommendations and CALM study, optimize patients based solely on lack of biological remission (CRP, calprotectin) can be discuss. If CALM study has showed that the intervention arm based on regular monitoring fecal calprotectin, CRP and/or CDAI to optimize patients under adalimumab was significantly associated to an increase rate of mucosal healing that the standard of care strategy based on only clinical activity, TDM was not available to guide drug optimization strategy.

Read the detailed description

To address these issues, for IFX or ADA therapy, several studies have proposed some algorithms according to which interventions are based on a combined assessment of IFX or ADA drug level and antibodies-to-IFX or ADA (ATI or AAA) levels at the time of therapeutic failure. Thus, IFX or ADA levels, classified as therapeutic or sub-therapeutic, and detectable or undetectable antibodies, are used to assess if LOR is likely due to immunogenicity, to non-immune-mediated pharmacokinetic problems or due to pharmacodynamic issues, and to guide interventions accordingly.

In the last AGA recommendations, the authors suggested that in case of secondary LOR under anti TNF drug with therapeutic levels to switch to another class (such as vedolizumab). However, recent studies showed that optimization of dose regimen of the same anti-TNF in these patients may still be associated with clinical response in 25% of patients. Indeed, in a recent bicentric, retrospective and non-randomized study, the investigators showed that IBD patients under ADA maintenance therapy who experience a secondary loss of response and in whom trough levels are >4.9µg/mL, swapping to another class was significantly better than optimizing ADA, in term of time without discontinuation of treatment.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's disease
  • Adalimumab
  • Vedolizumab
  • therapeutic strategy
  • Efficacy
  • biomarker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major patient and having given consent to participate in the study
  • Patients with Crohn's disease who have responded primary to Adalimumab princeps or similar bio with loss of response to Adalimumab (40 mg every two weeks).
  • Patient affiliated to or entitled under a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Pregnant woman
  • Patient unable to perform MRI or VCE or ileocolonoscopy or ultrasound less than one month before inclusion
  • Previous or current use of vedolizumab or ustekinumab for Crohn's disease or participation in a biological study
  • Concomitant use of immunomodulators
  • Patients on therapy
  • History of cancer
  • History of (HIV), immunodeficiency syndrome, central nervous system (CNS) demyelinating disease (including myelitis), neurological symptoms suggestive of demyelinating disease, chronic recurrent infection, active tuberculosis (received or untreated), severe infections such as sepsis and opportunistic infections
  • Patient with ileoanal pouchitis or ileorectal anastomosis
  • Patient with short small bowel syndrome as determined by investigator
  • Patients receiving total parenteral nutrition (TPN)
  • Patients receiving enteral nutrition
  • Patient under legal protection or unable to give consent
  • Hemorrhagic rectocolitis or indeterminate colitis
  • Patients treated with concomitant agents
  • Patient treated with an optimized dose of adalimumab
  • Primary non-responder to Adalimumab
  • Patient previously treated with infliximab or ustekinumab before adalimumab
  • Severe relapse defined by CDAI > 330
  • Patient with anoperineal Crohn's disease
  • Crohn's disease patient with transient or permanent stoma.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Adalimumab with optimisation

    Patients with Crohn's disease will be included. They will have Adalimumab with optimisation as treatment.

    Drug: Adalimumab

  • Experimental
    Vedolizumab

    Patients with Crohn's disease will be included. They will have Vedolizumab as treatment.

    Drug: Vedolizumab

Interventions

  • Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.

  • Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. ADA optimized versus Vedolizumab as second line

    The primary objective will be to compare the proportion of clinical and biomarker remission (composite score) in the two groups of CD patients by 24 weeks after inclusion.

    Time frame: Week 24

Secondary outcomes

  1. Proportion of deep remission

    To compare the proportion of deep remissions, the composite score is : * Clinical and biomarker remission at week 24 ; * AND Mucosal remission at week 24; * AND no treatment failure between inclusion and week 24.

    Time frame: Weeks 0; 24

  2. Proportion of clinical remission

    A patient is considered to be in clinical remission if they present: * A Crohn's Disease Activity Index (CDAI score) \< 150 at week 24 ; * OR a CDAI score ≥ 150 at week 24 AND a CDAI score \< 150 at inclusion AND an increase \< 70 points between inclusion and week 24. CDAI is the Crohn's disease activity score most commonly used in clinical trials. A CDAI below 150 corresponds to inactive Crohn's disease; between 150 and 450 to active Crohn's disease; above 450 to severe Crohn's disease.

    Time frame: Weeks 0; 24

  3. faecal calprotectin (microG / g)

    Biomarkers are considered to be standardised if the following are observed \- normalisation of faecal calprotectin: faecal calprotectin \< 250 µg/g at week 24.

    Time frame: Week 24

  4. serum C-reactive protein (CRP) mg/l

    Biomarkers are considered to be standardised if the following are observed \- Normalisation of serum C-reactive protein (CRP) : serum CRP \< 5 mg/L at week 24 ;

    Time frame: Week 24

  5. Proportion of endoscopic remissions according to Crohn's Disease Endoscopic Index score (CDEIS)

    A patient is considered to be in endoscopic remission if they have: \- a CDEIS score \< 3 at week 24 using ileocolonoscopy ; The CDEIS is an index of the severity of intestinal lesions caused by Crohn's disease. The CDEIS ranges from 0 to 44 0: no lesions 44: most severe lesions Endoscopic remission defined by a CDEIS ≤ 7

    Time frame: Week 24

  6. Proportion of endoscopic remissions according to Lewis score

    A patient is considered to be in endoscopic remission if they have: \- a Lewis score \< 135 at week 24 in the small bowel using VCE (video endoscopy); The Lewis score analyses 5 mucosal parameters for each of the four segments of the small bowel (duodenum, jejunum, proximal and distal ileum): erythema, oedema, presence of nodular lesions, ulcerations and stenosis. A Lewis score \< 135 indicates inactive disease.

    Time frame: Week 24

  7. Proportion of endoscopic remissions according to the number of ulcerations

    A patient is considered to be in endoscopic remission if they have: \- no ulceration using endoscopic video capsule (VCE) at week 24;

    Time frame: Week 24

  8. Proportion of endoscopic remissions according to the Magnetic Resonance Imaging (MRI) activity

    A patient is considered to be in endoscopic remission if they have: \- no activity on MRI at week 24 (defined as segmental MaRIA score \< 7); The MaRIA (Magnetic Resonance Index of Activity) scoring system is used to assess ileocolic Crohn's disease activity on contrast-enhanced MRI enterography. The segmental index represents the severity of disease in a segment of the bowel, while assessing six defined anatomical regions that can be combined to form an overall MaRIA index. The cut-off points for the MaRIA score are as follows: moderate disease: ≥7 severe disease: ≥11

    Time frame: Week 24

  9. Proportion of endoscopic remissions according to bowel thickness

    A patient is considered to be in endoscopic remission if they have: \- no bowel thickness on ultrasound at week 24 (\< 3mm with no other signs of activity).

    Time frame: Week 24

  10. Treatment failure

    Compare treatment failure at week 24 or week 52 in the 2 groups. Treatment failure is defined as: * The performance of a CD-related surgery between inclusion and week 24 ; * OR use of steroids between baseline and week 24; * OR treatment dose optimisation between inclusion and week 24; * OR a change in treatment between inclusion and week 24.

    Time frame: Weeks : 24; 52

  11. Adverse events

    Compare the percentage of adverse events in both arms at week 52

    Time frame: Week 24

  12. Symptomatic remission at week 24

    Symptomatic remission at week 24 is a composite criterion measured by PRO2 defined as: Stool frequency (SF) \< 3 with abdominal pain score (AP) \< 2 at week 24; AND absence of therapeutic failure between inclusion and week 24.

    Time frame: Week 24

  13. Changes in quality of life score (Inflammatory Bowel Disease Questionnaire (IBDQ)-32

    Compare evolution of IBDQ-32 in the two groups of patients between inclusion and week 24. The IBDQ-32 questionnaire consists of 32 questions. Each question is answered on a scale from 1 to 7, with 1 being the lowest score and 7 the highest. Adding up the different scores gives a total score, ranging from 32 (worst score) to 224 (best score). The higher the score, the better the quality of life.

    Time frame: Weeks : 0; 24

  14. Clinical and biomarker remission

    Compare rates of clinical and biomarker remission at week 12 and week 52.

    Time frame: Weeks : 12; 52

  15. Mucosal remission

    Rate of Mucosal remission at week 24. Mucosal remission is definied by ; * a CDEIS score \< 3 at week 24 using ileocolonoscopy ; The CDEIS is an index of the severity of intestinal lesions caused by Crohn's disease. * Or a Lewis score \< 135 at week 24 in the small bowel using VCE (video endoscopy) * Or no ulceration using endoscopic video capsule (VCE) at week 24; * Or no activity on MRI at week 24 (defined as segmental MaRIA score \< 7); * Or no bowel thickness on ultrasound at week 24 (\< 3mm with no other signs of activity).

    Time frame: Week 24

  16. Clinical Decision Support Tool (CDST) score

    Analyze the CDST score for prediction of remission under vedolizumab and adalimumab optimization. A CDST score : * \< 13 points is considered a low probability of remission; * Between 13 and 19 points is considered an intermediate probability of remission; * \> 19 points is considered a high probability of remission.

    Time frame: Week 52

  17. Pharmacodynamic failure

    Compare the efficacy of each strategy based on baseline serum ADA levels, classified into three groups: Pharmacodynamic failure: Therapeutic level of ADA in blood (\> 7.5 µg/mL) Pharmacokinetic failure: Subtherapeutic level of ADA in blood (\< 7.5 µg/mL) Immunogenic failure (undetectable serum ADA level with the presence of anti-ADA antibodies \>50 ng/mL).

    Time frame: Week 52

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 54 non-industry phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 71. This study's planned 36 months is below that.

Counting every sponsor, half of 70 studies reached it within 56 months; a quarter within 35 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 22, 2023
StartActual
Oct 31, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2028
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06180382
Collaborators
Takeda France
Responsible party
Sponsor
First posted
Dec 22, 2023
Start date
Oct 31, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
May 5, 2026

Study contacts

Mathilde BARRAU, MD
Contact
mathilde.barrau@chu-st-etienne.fr
(0)477829626 ext. +33
Sandra COURNIER, project manager
Contact
sandra.cournier@chu-st-etienne.fr
(0)477127652 ext. +33
Mathilde BARRAU, MD
principal investigator · CHU de Saint-Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Vedolizumab

Start the discussion